News articles about Novogen Limited (NASDAQ:NVGN) have been trending positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novogen Limited earned a daily sentiment score of 0.37 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.4175594308547 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Novogen Limited (NASDAQ NVGN) opened at 3.39 on Tuesday. The company’s market capitalization is $16.38 million. Novogen Limited has a one year low of $0.80 and a one year high of $9.76. The firm has a 50-day moving average of $2.32 and a 200 day moving average of $1.50.

Several research analysts have commented on NVGN shares. ValuEngine downgraded shares of Novogen Limited from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Novogen Limited from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/positive-news-coverage-somewhat-unlikely-to-impact-novogen-limited-nvgn-stock-price/1489805.html.

About Novogen Limited

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.

Insider Buying and Selling by Quarter for Novogen Limited (NASDAQ:NVGN)

Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.